Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text

Life Sciences, Immunology, Oncology +17

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Pietro Lampertico, Kosh Agarwal, Thomas Berg et al. · Journal of Hepatology · 2017 · 5.4K citations

Pharmacy, Infectious Diseases, Internal Medicine +16

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau et al. · The Lancet · 2017 · 4.3K citations · Full text

Medicine, Oncology, Pharmacology +13

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Norah A. Terrault, Anna S. Lok, Brian J. McMahon et al. · Hepatology · 2018 · 4.3K citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +17

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Julie R. Brahmer, Charles G. Drake, Ira Wollner et al. · Journal of Clinical Oncology · 2010 · 2.9K citations · Full text

Medicine, Oncology, Pharmacology +17